SCHEMBL6802132

SCHEMBL6802132

CCNC(=O)C1CCC(N)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR2 O60603 2/20 0.48
KMT2A Q03164 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GNAI3 P08754 1/20 0.41
GNAO1 P09471 1/20 0.41
GNAI1 P63096 1/20 0.41
NAAA Q02083 1/20 0.41
BCHE P06276 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
EPHX1 P07099 1/20 0.38
TRPA1 O75762 1/20 0.38
SMYD3 Q9H7B4 1/20 0.38
HSP90AB1 P08238 2/20 0.37
CYP3A4 P08684 1/20 0.36
RAB9A P51151 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1678458 0.89
SCHEMBL16430876 0.88 TLR2 (0.40) TLR2KMT2ASMN1; SMN2HSD17B10GNAI3
Hydrochloric Acid SCHEMBL28988641 0.87
SCHEMBL2226371 0.84 NAAA (0.50) TLR2KMT2ASMN1; SMN2HSD17B10GNAI3
SCHEMBL23890497 0.81 KMT2A (0.45) KMT2ASMN1; SMN2HSD17B10GNAI3GNAO1
SCHEMBL15199084 0.81 KMT2A (0.45) KMT2ASMN1; SMN2HSD17B10GNAI3GNAO1
SCHEMBL13753926 0.81 KMT2A (0.45) KMT2ASMN1; SMN2HSD17B10GNAI3GNAO1
SCHEMBL15199085 0.81 KMT2A (0.45) KMT2ASMN1; SMN2HSD17B10GNAI3GNAO1
SCHEMBL13255685 0.81 KMT2A (0.45) KMT2ASMN1; SMN2HSD17B10GNAI3GNAO1
SCHEMBL13321817 0.81 KMT2A (0.45) KMT2ASMN1; SMN2HSD17B10GNAI3GNAO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063701-A1 Piperidine derivatives and anti-platelet agents containing the same AJINOMOTO CO., INC (JP) 2004-04-01 US claimed
US-20020147195-A1 Piperidine derivatives and anti-platelet agents containing the same AJINOMOTO CO., INC. (JP) 2002-10-10 US claimed
US-20020019533-A1 PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME MAKINO SHINGO (JP) 2002-02-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019533-A1 PIPERIDINE DERIVATIVES AND ANTI-PLATELET AGENTS CONTAINING THE SAME HTR2A, PDGFRA, PDGFRB TLR2 657/4885KMT2A 1761/4885SMN1; SMN2 2817/4885
US-20020147195-A1 Piperidine derivatives and anti-platelet agents containing the same HTR2A, PDGFRA, PDGFRB TLR2 657/4885KMT2A 1761/4885SMN1; SMN2 2817/4885
US-20040063701-A1 Piperidine derivatives and anti-platelet agents containing the same HTR2A, PDGFRA, PDGFRB TLR2 657/4885KMT2A 1761/4885SMN1; SMN2 2817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.